Business Context and Reporting Period
Company: Pharming Group N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 22, 2026
Context: The filing announces positive Phase II topline data for leniolisib in patients with primary immunodeficiencies (PIDs) with immune dysregulation. The data was accepted as a late-breaking abstract for the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID) 2026.
Key Financial Metrics
This filing is a current report regarding clinical trial progress and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
- Study Design: Single-arm, open-label, intra-patient dose-escalation Phase II study involving 13 subjects with genetically defined PIDs.
- Efficacy: Leniolisib demonstrated clinical improvements in immune dysregulation, including a mean 26.4% spleen volume reduction (SVR) and reductions in the size of index lesions.
- Safety: The drug was generally well-tolerated. Infections were the most common adverse events, with no new safety signals identified.
- Population: Of the 13 enrolled patients, nine also had a diagnosis of common variable immunodeficiency (CVID).
Guidance, Outlook, and Risks
- Upcoming Data: Pharming expects to report topline results from a separate Phase II trial of leniolisib in CVID patients in Q4 2026.
- Strategic Outlook: Management views these results as a step toward addressing immune dysregulation in PIDs beyond Activated PI3K Delta Syndrome (APDS), potentially benefiting a larger patient population. Future plans for a registrational study in the broader CVID population will be informed by the Q4 2026 results.
- Risks: The filing includes standard forward-looking statement disclaimers regarding clinical trial progress, regulatory approvals, and commercial prospects. Actual results may differ materially from expectations due to known and unknown risks.
Investor Verification Checklist
- Verify the full presentation of data at the ESID 2026 conference (October 14-17, 2026) for detailed efficacy and safety breakdowns.
- Monitor the Q4 2026 announcement for topline results of the separate Phase II trial in CVID patients.
- Review the company's 2025 Annual Report (Form 20-F) for detailed financial position, cash runway, and comprehensive risk factors not included in this press release.
- Confirm regulatory status updates for leniolisib in countries where it is currently under review for APDS treatment.